A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Persistent or clinically significant diarrhea, nausea, or abdominal pain.
• •Severe odynophagia.
• •Other gastrointestinal (GI) symptoms or uncontrolled GI disease.
• •Active CMV disease of the GI tract (e.g., CMV colitis, CMV esophagitis).
• •Ocular media opacities (corneal, lenticular, or vitreal) that prevent ophthalmologic retinal assessments.
• •Dementia, decreased mentation, or other encephalopathic signs and symptoms that would preclude informed consent or study compliance.
• •Concurrent Medication:
• •Excluded:
• •Acyclovir sodium (Zovirax) by any route other than topical.
• •Valacyclovir.
• •Brovavir.
• •Vidarabine.
• •Amantadine hydrochloride.
• •Cytarabine.
• •Idoxuridine.
• •Ribavirin.
• •Interferon.
• •Foscarnet (non-nucleoside pyrophosphate analogue).
• •CMV hyperimmune globulin.
• •Soluble CD4.
• •Trichosanthin (Compound Q).
• •Imipenem-cilastatin.
• •Isoprinosine.
• •Levamisole.
• •Other investigational drugs.
• •Patients with the following prior condition are excluded:
• •History of hypersensitivity to acyclovir or ganciclovir.
• •Prior Medication:
• •Excluded:
• •More than three induction regimens with intravenous anti-CMV therapy.
• •Any prior oral ganciclovir.